Neuroscientific Biopharmaceuticals (ASX:NSB) - Investor Webinar - 16 June 2026

Neuroscientific Biopharmaceuticals Ltd (ASX:NSB) recent investor webinar to provide an update on their StemSmart technology and clinical development program for Crohn’s disease. In this webinar, CEO Nathan Smith discusses the Company’s recent Special Access Program results, where four out of five patients treated with StemSmart achieved a successful clinical response. The webinar also includes insights from Chief Scientific Officer Dr Marian Sturm, who pioneered the development of StemSmart, during the Q&A session. StemSmart is a mesenchymal stem cell therapy being developed to target immune mediated inflammatory diseases, with an initial focus on severe Crohn’s disease, including refractory and fistulising Crohn’s disease. Key topics covered include: Neuroscientific’s clinical development strategy for StemSmart The unmet medical need in severe Crohn’s disease Special Access Program results in fistulising Crohn’s disease Planned phase two clinical trials for refractory and fistulising Crohn’s disease StemSmart’s mechanism of action and safety profile Manufacturing transfer and regulatory pathway Commercialisation strategy and future clinical milestones Watch the full webinar to hear more from NSB CEO Nathan Smith and CSO Dr Marian Sturm. ASX:NSB -------------------------------------------------------------------------- ABOUT NEUROSCIENTIFIC BIOPHARMACEUTICALS ASX:NSB NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company’s research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need. Targeting Crohn’s Disease with StemSmart™ Technology Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the progression to Phase 2 clinical trials to further evaluate safety and efficacy of its proprietary StemSmart technology in refractory and fistulising Crohn’s disease — severe and treatment-resistant forms of the condition. These clinical trials are supported by the favourable outcomes of the previous successful Phase 2 clinical trial in refractory Crohn’s disease and the recent announcement of 80% clinical response under the Company’s Special Access Program in fistulising Crohn’s disease. This initiative aligns with NSB’s broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn’s disease, for whom current therapies remain inadequate. -------------------------------------------------------------------------------- Jane Morgan Management is a boutique Investor Relations and Media Communications consultancy for ASX-listed companies. As we approach our 20th year in 2026, we've supported more than 250 ASX-listed clients across mining, resources, biotech, fintech, technology and consumer sectors. Website | http://www.janemorganmanagement.com.au LinkedIn |   / janemorganmanagement   Twitter |   / jmm_australia